Bracco Imaging S.p.A., a company in the diagnostic imaging business, announced today that its contrast agent SonoVue (sulphur hexafluoride microbubbles) is the first ultrasound contrast agent to obtain approval in the European Union for its use in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients.
The new product solutions of medical technology company Richard Wolf were presented at the Congress of the European Association of Urology (EAU) in several live operations and pre-recorded videos.
New research confirms that an innovative procedure combining MRI and ultrasound to create a 3D image of the prostate can more accurately locate suspicious areas and help diagnose whether it’s prostate cancer.
Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden.
Ultrasound biopsy is rather unreliable to detect or exclude prostate cancer: many tumours are difficult – or impossible – to visualise sonographically and tissue sampling is haphazard rather than targeted.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Urinary tract infections caused by catheterisation are a common and nasty affliction for the disabled, elderly and hospital patients.